Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Japanese health regulator approves Eylea label expansion

    Headlines

    Mon, 22 Sep 2014

    Welfare approves the use of Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) injection ..... neovascularization (myopic CNV). Eylea is already approved for sale ..... vein occlusion (CRVO). Eylea is marketed in Japan by Bayer

  2. Regeneron Is Regenerating Growth In My Portfolio Once Again

    Headlines

    Sun, 21 Sep 2014

    up some gains. I ended up buying shares of Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN ) because I wanted to buy back into the growth stock. Regeneron is a fully integrated biopharmaceutical company

  3. BTD tag for Eylea for diabetic retinopathy in DME

    Headlines

    Tue, 16 Sep 2014

    The FDA designates Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea ( aflibercept ) a Breakthough Therapy (BTD) for the ..... of more-intensive agency guidance and discussion. Eylea is currently approved for the treatment of wet age

  4. Sanofi: Riding The Growth Trend

    Headlines

    Mon, 8 Sep 2014

    analyze Sanofi's pipeline and its valuation. Positive Data from Sanofi and Regeneron Pharmaceutical's Cholesterol Drug Sanofi and Regeneron Pharmaceuticals (NASDAQ: REGN ) recently announced positive results from a Phase 3 ODYSSEY trial of Alirocumab

  5. There Is Further Upside Potential In Regeneron Pharmaceuticals

    Headlines

    Mon, 8 Sep 2014

    general, Regeneron Pharmaceuticals Inc . (NASDAQ: REGN ) is an exception ..... surprise. Regeneron 's EYLEA is on track ..... Recently, EYLEA also received ..... alirocumab. Regeneron and Sanofi ..... upside in Regeneron even as the

  6. EC approves Eylea label expansion

    Headlines

    Mon, 11 Aug 2014

    The European Commission approves Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements

  7. The Case That Regeneron May Be Significantly Undervalued

    Headlines

    Fri, 8 Aug 2014

    appearances may be deceiving. Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN ) is in my view that sort ..... hence. This article evaluates REGN using a sum-of-the-parts ..... pinpoint yet. Introduction : Regeneron is a world-class developer

  8. New Morningstar Analyst Report for Regeneron Pharmaceuticals Inc

    Stock Reports

    Tue, 5 Aug 2014

    colorectal cancer trials, Regeneron 's oncology drug Zaltrap ..... of its high cost. Eylea is on track to capture ..... acquisition down the road. Regeneron 's prolific monoclonal ..... 6 million in 2012. Regeneron Pharmaceuticals discovers, develops ..... marketed products: Eylea , approved for wet

  9. Regeneron Reports Solid 2Q Eylea Sales, Continued Pipeline Progress; Maintaining Fair Value

    Commentary

    Tue, 5 Aug 2014

    Regeneron reported second-quarter results that ..... better than anticipated, with U.S. Eylea sales rebounding strongly after a sluggish ..... first-quarter results. Rest of world Eylea sales, as reported by partner Bayer ..... Despite higher SG&A costs related to Eylea 's commercialization and increased ..... hypercholesterolemia patients. Importantly, Regeneron also disclosed that in a prespecified

  10. A New Indication for Eylea and Positive Phase III Results for Alirocumab; Raising FVE

    Commentary

    Wed, 30 Jul 2014

    Regeneron has reported two meaningful pipeline ..... Food and Drug Administration approved Eylea on July 29 in diabetic macular edema ..... treating high cholesterol. While the Eylea news was expected, the positive alirocumab ..... narrow moat, positive trend rating for Regeneron . While the DME approval was expected ..... estimates, the new indication should allow Eylea sales to re-accelerate in the second

« Prev12345Next »
Content Partners